Professor Erlie Jiang: Platform Synergy, Evidence Empowerment, and Grassroots Equity — Outcomes of the 2025 CSCO Leukemia Guideline Roadshow and the 2026 Strategic Blueprint

Professor Erlie Jiang: Platform Synergy, Evidence Empowerment, and Grassroots Equity — Outcomes of the 2025 CSCO Leukemia Guideline Roadshow and the 2026 Strategic Blueprint

From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. Guided by the overarching vision of “Greater Hematology, Greater Public Health, and Greater Health,” CSCO’s hematology committees have built a four-pillar framework centered on standardization, clinical support, collaboration, and prognostic assessment, and a three-core value system emphasizing guideline implementation, resource decentralization, and academic empowerment.
Professor Lugui Qiu: Upholding Integrity, Driving Innovation—CSCO Myeloma Expert Committee 2025 Work Summary and 2026 Strategic Plan

Professor Lugui Qiu: Upholding Integrity, Driving Innovation—CSCO Myeloma Expert Committee 2025 Work Summary and 2026 Strategic Plan

From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. As a malignant plasma cell disorder predominantly affecting older adults, multiple myeloma (MM) requires continuous advancement in standardized diagnosis, scientific innovation, and patient-centered management, all of which are critical to the high-quality development of hematologic oncology in China.
Annual Review | Professor Xiuli Ju: Advances in the Diagnosis and Treatment of Pediatric Mature B-Cell Lymphoma

Annual Review | Professor Xiuli Ju: Advances in the Diagnosis and Treatment of Pediatric Mature B-Cell Lymphoma

From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. Leading experts and scholars from across China presented advances in both basic and clinical research in leukemia, lymphoma, and myeloma, addressing key challenges in real-world practice and exploring new therapeutic directions.
Professor Thomas Powles: How Will ADC–Immunotherapy Combinations and ctDNA Reshape Perioperative Treatment in Bladder Cancer?

Professor Thomas Powles: How Will ADC–Immunotherapy Combinations and ctDNA Reshape Perioperative Treatment in Bladder Cancer?

The combination of antibody–drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) is rapidly transforming the clinical management of urothelial carcinoma. Meanwhile, circulating tumor DNA (ctDNA) is emerging as a highly promising biomarker, offering critical support for precision medicine and bladder-preserving treatment strategies.
Professor Xieqiao Yan: Optimizing Post-Failure Treatment Strategies in Renal Cell Carcinoma After Targeted-Immunotherapy—Exploring New Pathways for Later-Line Therapy

Professor Xieqiao Yan: Optimizing Post-Failure Treatment Strategies in Renal Cell Carcinoma After Targeted-Immunotherapy—Exploring New Pathways for Later-Line Therapy

From January 10 to 11, 2026, the Beijing Young Urologic Oncology Physicians Academic Exchange Conference was successfully held in Beijing. The meeting brought together leading experts and young physicians in urologic oncology to discuss cutting-edge scientific advances and key clinical challenges, with the goal of fostering academic innovation and supporting the growth of emerging clinicians.
Professor Ludong Qiao Interprets the IDSA Guidelines on Complicated Urinary Tract Infections: Rational Use of Cefiderocol and Novel Antibiotic Combinations

Professor Ludong Qiao Interprets the IDSA Guidelines on Complicated Urinary Tract Infections: Rational Use of Cefiderocol and Novel Antibiotic Combinations

The Infectious Diseases Society of America (IDSA) has recently released its Clinical Practice Guidelines for the Treatment and Management of Complicated Urinary Tract Infections (cUTI)—the first IDSA guideline dedicated specifically to cUTI. The updated guideline revises the definition of cUTI and proposes a four-step framework to support individualized empiric treatment decisions.
Professor Yonghong Li: Neoadjuvant Therapy for Locally Advanced Prostate Cancer—A Chinese Perspective and Clinical Balance

Professor Yonghong Li: Neoadjuvant Therapy for Locally Advanced Prostate Cancer—A Chinese Perspective and Clinical Balance

From January 10 to 11, 2026, the Beijing Young Urologic Oncology Physicians Academic Exchange Conference concluded successfully in Beijing. The meeting brought together leading experts and young physicians in urologic oncology to discuss cutting-edge scientific advances and clinical challenges, with the goal of fostering innovation and professional development among emerging clinicians
Research Breakthrough by Professor Qiang Lü’s Team at Jiangsu Provincial People’s Hospital: Imaging AI Enables Personalized Prognosis Prediction and Treatment Response Assessment in Bladder Cancer

Research Breakthrough by Professor Qiang Lü’s Team at Jiangsu Provincial People’s Hospital: Imaging AI Enables Personalized Prognosis Prediction and Treatment Response Assessment in Bladder Cancer

Recently, the Department of Urology at Jiangsu Provincial People’s Hospital, led by Professor Qiang Lü, published a multicenter study in EClinicalMedicine (CAS Zone 1, Impact Factor = 10.0). By integrating multicenter MRI data, the research team developed a multimodal fusion–based deep learning model designed to achieve noninvasive preoperative survival prediction in bladder cancer patients.